Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 45.75 Million USD | 114.2% |
| 2022 | 22.95 Million USD | -54.12% |
| 2021 | 50.02 Million USD | -51.64% |
| 2020 | 103.43 Million USD | 160.25% |
| 2019 | 39.74 Million USD | 80.2% |
| 2018 | 22.05 Million USD | 49.08% |
| 2017 | 14.79 Million USD | 44.69% |
| 2016 | 10.22 Million USD | 62.17% |
| 2015 | 6.3 Million USD | 37.77% |
| 2014 | 4.57 Million USD | -16.19% |
| 2013 | 5.46 Million USD | 9.46% |
| 2012 | 4.98 Million USD | 6794.85% |
| 2011 | 72.35 Thousand USD | 241.72% |
| 2010 | 21.17 Thousand USD | -17.45% |
| 2009 | 25.64 Thousand USD | 754.93% |
| 2008 | 3000.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 8.26 Million USD | -74.47% |
| 2024 Q2 | 3.31 Million USD | -59.83% |
| 2023 Q3 | 2.05 Million USD | -70.97% |
| 2023 Q1 | 7.52 Million USD | -42.4% |
| 2023 FY | 49.16 Million USD | 114.2% |
| 2023 Q2 | 7.07 Million USD | -6.03% |
| 2023 Q4 | 32.36 Million USD | 1476.28% |
| 2022 Q1 | 9.73 Million USD | -68.92% |
| 2022 FY | 22.95 Million USD | -54.12% |
| 2022 Q4 | 13.06 Million USD | 279.11% |
| 2022 Q3 | 3.44 Million USD | 8.29% |
| 2022 Q2 | 3.18 Million USD | -67.3% |
| 2021 Q4 | 31.32 Million USD | 240.14% |
| 2021 Q1 | 4.15 Million USD | -83.11% |
| 2021 FY | 50.02 Million USD | -51.64% |
| 2021 Q3 | 9.2 Million USD | 72.47% |
| 2021 Q2 | 5.33 Million USD | 28.43% |
| 2020 Q2 | 28.27 Million USD | 235.01% |
| 2020 Q1 | 8.44 Million USD | -35.59% |
| 2020 Q3 | 11.07 Million USD | -60.84% |
| 2020 Q4 | 24.6 Million USD | 122.19% |
| 2020 FY | 103.43 Million USD | 160.25% |
| 2019 Q3 | 7.22 Million USD | -11.25% |
| 2019 Q1 | 11.26 Million USD | 15.59% |
| 2019 Q2 | 8.14 Million USD | -27.73% |
| 2019 FY | 39.74 Million USD | 80.2% |
| 2019 Q4 | 13.1 Million USD | 81.33% |
| 2018 Q2 | 4.55 Million USD | 7.71% |
| 2018 FY | 22.05 Million USD | 49.08% |
| 2018 Q3 | 3.52 Million USD | -22.7% |
| 2018 Q4 | 9.74 Million USD | 176.77% |
| 2018 Q1 | 4.23 Million USD | 72.65% |
| 2017 Q3 | 3.83 Million USD | -16.25% |
| 2017 Q4 | 2.45 Million USD | -36.1% |
| 2017 FY | 14.79 Million USD | 44.69% |
| 2017 Q2 | 4.57 Million USD | 16.4% |
| 2017 Q1 | 3.93 Million USD | 44.22% |
| 2016 FY | 10.22 Million USD | 62.17% |
| 2016 Q4 | 2.72 Million USD | 10.76% |
| 2016 Q3 | 2.46 Million USD | -21.62% |
| 2016 Q2 | 3.14 Million USD | 65.75% |
| 2016 Q1 | 1.89 Million USD | -1.97% |
| 2015 Q2 | 1.88 Million USD | 125.51% |
| 2015 Q3 | 1.65 Million USD | -12.09% |
| 2015 FY | 6.3 Million USD | 37.77% |
| 2015 Q4 | 1.93 Million USD | 16.82% |
| 2015 Q1 | 834.7 Thousand USD | 37.18% |
| 2014 Q1 | 1.11 Million USD | -33.72% |
| 2014 Q4 | 608.47 Thousand USD | -52.67% |
| 2014 FY | 4.57 Million USD | -16.19% |
| 2014 Q3 | 1.28 Million USD | -17.86% |
| 2014 Q2 | 1.56 Million USD | 40.1% |
| 2013 Q3 | 1.16 Million USD | -10.07% |
| 2013 Q1 | 1.32 Million USD | -3.69% |
| 2013 FY | 5.46 Million USD | 9.46% |
| 2013 Q4 | 1.68 Million USD | 45.05% |
| 2013 Q2 | 1.29 Million USD | -2.12% |
| 2012 FY | 4.98 Million USD | 6794.85% |
| 2012 Q4 | 1.37 Million USD | -27.43% |
| 2012 Q3 | 1.88 Million USD | 115.94% |
| 2012 Q2 | 874.82 Thousand USD | 2.47% |
| 2012 Q1 | 853.76 Thousand USD | 1278.9% |
| 2011 Q1 | 5436.00 USD | -31.98% |
| 2011 FY | 72.35 Thousand USD | 241.72% |
| 2011 Q4 | 61.91 Thousand USD | 2163.84% |
| 2011 Q3 | 2735.00 USD | 20.75% |
| 2011 Q2 | 2265.00 USD | -58.33% |
| 2010 Q4 | 7992.00 USD | 44.99% |
| 2010 Q3 | 5512.00 USD | 12.72% |
| 2010 FY | 21.17 Thousand USD | -17.45% |
| 2010 Q2 | 4890.00 USD | 75.96% |
| 2010 Q1 | 2779.00 USD | -45.14% |
| 2009 Q1 | 1706.00 USD | 0.0% |
| 2009 Q4 | 5066.00 USD | -62.16% |
| 2009 Q3 | 13.38 Thousand USD | 144.06% |
| 2009 FY | 25.64 Thousand USD | 754.93% |
| 2009 Q2 | 5486.00 USD | 221.57% |
| 2008 FY | 3000.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -6819.962% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -393.71% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -52.559% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 31.855% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -188.815% |
| Better Therapeutics, Inc. | 38.26 Million USD | -19.589% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -12.455% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -269.225% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -35.2% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -32.941% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 57.814% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -4508.842% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -40.406% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 2.543% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -3666.976% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -129.481% |
| Molecular Templates, Inc. | 63.09 Million USD | 27.475% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -228.44% |
| NexImmune, Inc. | 28.16 Million USD | -62.446% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -78.411% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -62225.651% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -183.408% |
| Scopus BioPharma Inc. | 11.71 Million USD | -290.589% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 88.662% |
| Statera Biopharma, Inc. | 28.82 Million USD | -58.716% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -141.73% |
| Trevena, Inc. | 38.41 Million USD | -19.119% |
| Vaxxinity, Inc. | 56.05 Million USD | 18.365% |
| Vaccinex, Inc. | 23.45 Million USD | -95.084% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -4270.388% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 9.737% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -528.995% |